Insmed Projects Revenue Growth and Advances Drug Pipeline

The latest announcement is out from Insmed ( (INSM) ).

Insmed announced significant commercial and clinical progress, forecasting 2025 global revenues for ARIKAYCE between $405 million and $425 million, which represents continued growth. The company submitted a new drug application for brensocatib to the FDA and plans to launch it in the U.S. in the third quarter of 2025, pending approval. Insmed completed enrollment for various clinical trials, including the Phase 2 study for TPIP in PAH and the Phase 3 ENCORE trial for ARIKAYCE, with results expected in the coming years. Additionally, they plan to initiate a clinical trial for their gene therapy, INS1201, in patients with DMD in the first half of 2025.

More about Insmed

Insmed Incorporated is a global biopharmaceutical company focused on developing first- and best-in-class therapies to transform the lives of patients facing serious diseases. Its primary products include ARIKAYCE, a novel inhaled antibiotic for lung infections, and brensocatib, a small molecule inhibitor for bronchiectasis and other neutrophil-mediated diseases.

YTD Price Performance: -6.05%

Average Trading Volume: 1,542,562

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $11.76B

See more insights into INSM stock on TipRanks’ Stock Analysis page.